SCHEMBL5659032

SCHEMBL5659032

CC(C)(C)c1ccc(C(=O)Nc2nc(CO)cs2)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCD O00767 3/20 0.56
MAPT P10636 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.53
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
TAS1R2 Q8TE23 1/20 0.53
KDM4E B2RXH2 4/20 0.52
RAB9A P51151 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 3/20 0.51
PDE5A O76074 2/20 0.51
TRPV1 Q8NER1 1/20 0.48
MAP3K5 Q99683 1/20 0.48
TYR P14679 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91387 0.89 MAPT (0.55) MAPTSMN1; SMN2TAS1R3TAS1R1TAS1R2
SCHEMBL5659620 0.88 KMT2A (0.59) SCDMAPTSMN1; SMN2TAS1R3TAS1R1
SCHEMBL77958 0.82 SMN1; SMN2 (0.77) MAPTSMN1; SMN2TAS1R3TAS1R1TAS1R2
SCHEMBL24769869 0.78 KDM4E (0.46) MAPTSMN1; SMN2TAS1R3TAS1R1TAS1R2
SCHEMBL3933173 0.75 SMN1; SMN2 (0.73) MAPTSMN1; SMN2KDM4ERAB9AKMT2A
SCHEMBL4746841 0.74 ALDH1A1 (0.63) SCDMAPTSMN1; SMN2KDM4ERAB9A
SCHEMBL16434495 0.74 LMNA (0.74) MAPTSMN1; SMN2KDM4ERAB9AMEN1
SCHEMBL20791858 0.73 SMN1; SMN2 (0.77) MAPTSMN1; SMN2TAS1R3TAS1R1TAS1R2
SCHEMBL1030124 0.73 PI4KB (0.50) SMN1; SMN2RAB9AKMT2ANPC1MAPK1
SCHEMBL91391 0.73 KDM4E (0.69) SCDMAPTSMN1; SMN2KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241781-B2 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
EP-1671969-A2 Thiazolyl inhibitors of tec family tyrosine kinases Bristol-Myers Squibb Company (US) 2006-06-21 EP disclosed
US-7037926-B2 Thiazolyl inhibitors of Tec family tyrosine kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
EP-1347971-B1 THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES BRISTOL MYERS SQUIBB CO (US) 2006-03-01 EP disclosed
US-20060030598-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JOEL C 2006-02-09 US disclosed
US-6958336-B2 Thiazolyl inhibitors of Tec family tyrosine kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-25 US disclosed
US-6956045-B2 Thiazolyl inhibitors of Tec family tyrosine kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-18 US disclosed
US-6953795-B2 Thiazolyl inhibitors of Tec family tyrosine kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-11 US disclosed
US-20040110752-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JOEL C (US) 2004-06-10 US disclosed
US-20040077695-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JO I C (US) 2004-04-22 US disclosed
US-20040067990-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JOEL C (US) 2004-04-08 US disclosed
US-20040067989-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JOEL C (US) 2004-04-08 US disclosed
US-6706717-B2 ANTICANCER AGENTS; IMMUNOLOGY DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB COMPANY 2004-03-16 US disclosed
US-20030069238-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BRISTOL-MYERS SQUIBB COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077695-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK SCD 4484/4885MAPT 1090/4885SMN1; SMN2 4593/4885
US-20040067990-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK SCD 4484/4885MAPT 1090/4885SMN1; SMN2 4593/4885
US-20040067989-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK SCD 4484/4885MAPT 1090/4885SMN1; SMN2 4593/4885
US-20030069238-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK SCD 4484/4885MAPT 1090/4885SMN1; SMN2 4593/4885
US-20060030598-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK SCD 4484/4885MAPT 1090/4885SMN1; SMN2 4593/4885
US-20040110752-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK SCD 4484/4885MAPT 1090/4885SMN1; SMN2 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.